BioCentury | Dec 24, 2012
Company News

DUSA, Sun Pharmaceutical deal

...Sun completed its tender offer to acquire DUSA for $8 per share in cash, or about...
...Sun said it would complete the acquisition via a short-form merger (see BioCentury, Nov. 12). DUSA Pharmaceuticals Inc....
BioCentury | Nov 12, 2012
Finance

Highlights of weekly biotech stock moves

...rights to Xiaflex from BioSpecifics Technologies Corp. (NASDAQ:BSTC), which was off $0.54 to $15.03. DUSA Pharmaceuticals Inc. (NASDAQ:DUSA...
...to DUSA's close of $5.78 on Nov. 7, before the deal was announced. Last week, DUSA...
BioCentury | Nov 12, 2012
Company News

DUSA, Sun Pharmaceutical deal

...Sun will acquire DUSA for $8 per share in cash, or about $230 million. The price...
...per share in cash, or about $230 million. The price is a 38% premium to DUSA's...
...Light Photodynamic Therapy Illuminator (BLU-U). Leerink advised DUSA while Reed Smith was legal advisor. DUSA Pharmaceuticals Inc. (NASDAQ:DUSA...
BioCentury | Nov 9, 2012
Company News

Sun to acquire DUSA

...Sun Pharmaceutical Industries Ltd. (BSE:524715; NSE:SUNPHARMA) will acquire dermatology company DUSA Pharmaceuticals Inc. (NASDAQ:DUSA) for $8 per share...
...per share in cash, or about $230 million. The price is a 38% premium to DUSA's...
...Wednesday, before the deal was announced. The boards of both companies have approved the deal. DUSA's...
BioCentury | Sep 17, 2012
Finance

Highlights of weekly biotech stock moves

...to $76.67. DUSA Pharmaceuticals Inc. (NASDAQ:DUSA) gained $0.40 to $5.79 last week after Levulan Kerastick followed by DUSA's...
BioCentury | Sep 17, 2012
Clinical News

Levulan PDT aminolevulinic acid: Phase II data

...broad area application of Levulan Kerastick for 3 hours with or without occlusion followed by DUSA's...
...in the U.S. to treat minimally to moderately thick AK of the face and scalp. DUSA...
...company's basis for seeking an expanded label and for future development of the product. DUSA Pharmaceuticals Inc. (NASDAQ:DUSA...
BioCentury | Sep 14, 2012
Clinical News

DUSA up on actinic keratosis data

...DUSA Pharmaceuticals Inc. (NASDAQ:DUSA) gained $0.37 to $5.75 on Thursday after Levulan Kerastick followed by DUSA's...
...in the U.S. to treat minimally to moderately thick AK of the face and scalp. DUSA...
BioCentury | Jul 26, 2010
Company News

Nitric BioTherapeutics board of directors update

...Infectious, Dermatology Appointed: Al Altomari as executive chairman, a director at Auxilium Pharmaceuticals Inc. , DUSA Pharmaceuticals Inc....
BioCentury | Nov 16, 2009
Clinical News

Levulan PDT aminolevulinic acid: Pilot trial data

...heart transplant over the past 5-30 years showed that topical Levulan PDT applied prior to DUSA's...
...recurrence of non-melanoma skin cancer (NMSC) in high-risk chronically immunosuppressed solid organ transplant recipients. DUSA Pharmaceuticals Inc. (NASDAQ:DUSA...
BioCentury | Aug 17, 2009
Clinical News

Levulan PDT aminolevulinic acid regulatory update

...be over 200,000 patients, which is the maximum number of patients allowed under Orphan legislation. DUSA...
...prevent recurrence of non-melanoma skin cancer in high-risk, chronically immunosuppressed solid organ transplant recipients. DUSA Pharmaceuticals Inc. (NASDAQ:DUSA...
Items per page:
1 - 10 of 118
BioCentury | Dec 24, 2012
Company News

DUSA, Sun Pharmaceutical deal

...Sun completed its tender offer to acquire DUSA for $8 per share in cash, or about...
...Sun said it would complete the acquisition via a short-form merger (see BioCentury, Nov. 12). DUSA Pharmaceuticals Inc....
BioCentury | Nov 12, 2012
Finance

Highlights of weekly biotech stock moves

...rights to Xiaflex from BioSpecifics Technologies Corp. (NASDAQ:BSTC), which was off $0.54 to $15.03. DUSA Pharmaceuticals Inc. (NASDAQ:DUSA...
...to DUSA's close of $5.78 on Nov. 7, before the deal was announced. Last week, DUSA...
BioCentury | Nov 12, 2012
Company News

DUSA, Sun Pharmaceutical deal

...Sun will acquire DUSA for $8 per share in cash, or about $230 million. The price...
...per share in cash, or about $230 million. The price is a 38% premium to DUSA's...
...Light Photodynamic Therapy Illuminator (BLU-U). Leerink advised DUSA while Reed Smith was legal advisor. DUSA Pharmaceuticals Inc. (NASDAQ:DUSA...
BioCentury | Nov 9, 2012
Company News

Sun to acquire DUSA

...Sun Pharmaceutical Industries Ltd. (BSE:524715; NSE:SUNPHARMA) will acquire dermatology company DUSA Pharmaceuticals Inc. (NASDAQ:DUSA) for $8 per share...
...per share in cash, or about $230 million. The price is a 38% premium to DUSA's...
...Wednesday, before the deal was announced. The boards of both companies have approved the deal. DUSA's...
BioCentury | Sep 17, 2012
Finance

Highlights of weekly biotech stock moves

...to $76.67. DUSA Pharmaceuticals Inc. (NASDAQ:DUSA) gained $0.40 to $5.79 last week after Levulan Kerastick followed by DUSA's...
BioCentury | Sep 17, 2012
Clinical News

Levulan PDT aminolevulinic acid: Phase II data

...broad area application of Levulan Kerastick for 3 hours with or without occlusion followed by DUSA's...
...in the U.S. to treat minimally to moderately thick AK of the face and scalp. DUSA...
...company's basis for seeking an expanded label and for future development of the product. DUSA Pharmaceuticals Inc. (NASDAQ:DUSA...
BioCentury | Sep 14, 2012
Clinical News

DUSA up on actinic keratosis data

...DUSA Pharmaceuticals Inc. (NASDAQ:DUSA) gained $0.37 to $5.75 on Thursday after Levulan Kerastick followed by DUSA's...
...in the U.S. to treat minimally to moderately thick AK of the face and scalp. DUSA...
BioCentury | Jul 26, 2010
Company News

Nitric BioTherapeutics board of directors update

...Infectious, Dermatology Appointed: Al Altomari as executive chairman, a director at Auxilium Pharmaceuticals Inc. , DUSA Pharmaceuticals Inc....
BioCentury | Nov 16, 2009
Clinical News

Levulan PDT aminolevulinic acid: Pilot trial data

...heart transplant over the past 5-30 years showed that topical Levulan PDT applied prior to DUSA's...
...recurrence of non-melanoma skin cancer (NMSC) in high-risk chronically immunosuppressed solid organ transplant recipients. DUSA Pharmaceuticals Inc. (NASDAQ:DUSA...
BioCentury | Aug 17, 2009
Clinical News

Levulan PDT aminolevulinic acid regulatory update

...be over 200,000 patients, which is the maximum number of patients allowed under Orphan legislation. DUSA...
...prevent recurrence of non-melanoma skin cancer in high-risk, chronically immunosuppressed solid organ transplant recipients. DUSA Pharmaceuticals Inc. (NASDAQ:DUSA...
Items per page:
1 - 10 of 118